Knee osteoarthritis with obesity — indication assessment
Degenerative joint disease of the knee with radiographic or symptomatic confirmation, occurring with obesity as a mechanical and inflammatory contributor.
§1Assessment
§1.1Definition
Degenerative joint disease of the knee with radiographic or symptomatic confirmation, occurring with obesity as a mechanical and inflammatory contributor.
§1.2Anchor and additional outcomes
The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.
- WOMAC pain subscale
- Physical function score
- Analgesic use
- Progression to arthroplasty
§1.3State of the evidence
The Institute assesses 3 compounds in this indication, drawing on 11 trial records and 0 evidence syntheses. No compound is graded above low certainty in this indication, which the Institute records as the principal finding for it.[1,2]
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology 2001;142(12):5182–5189. doi:10.1210/endo.142.12.8522 · PMID 11713213
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2019;11(6):663–673. doi:10.1586/14789450.2014.965158
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.